(HealthDay News) — Physicians vary in attitudes about predictive multiplex somatic genetic testing and their plans to incorporate its use into practice, according to research published online March 24 in the Journal of Clinical Oncology.
Stacy W. Gray, MD, of the Dana-Farber Cancer Institute in Boston, and colleagues surveyed 160 physicians (57% medical oncologists, 29% surgeons, and 14% radiation oncologists) at a major cancer center. The researchers sought to assess current use of somatic testing, attitudes about multiplex testing, and genomic confidence.
The researchers found that, among physician respondents, 22% reported low confidence in their genomic knowledge. Physicians with higher genomic confidence were more likely to report that they would test a majority of patients (adjusted odds ratio [aOR], 6.09; 95% confidence interval [CI], 2.1 to 17.5) and use actionable test results (aOR, 2.46; 95% CI, 1.2 to 5.2) or potentially actionable test results (aOR, 2.89; 95% CI, 1.1 to 7.9) to guide treatment recommendations.
A sizable number of physicians (42%) supported disclosure of uncertain genomic findings to patients.
“These findings suggest the need for additional research to understand how genomic confidence is related to knowledge and practical abilities, and how high confidence will affect clinical behaviors with regard to multiplex somatic testing moving forward,” wrrote the author of an accompanying editorial.
One author disclosed financial ties to Merrimack Pharmaceuticals.
- Gray SW, Hicks-Courant S, Cronin A, et al. Physicians’ Attitudes About Multiplex Tumor Genomic Testing. J Clin Oncol. 2014; doi:10.1200/JCO.2013.52.4298.
- Hall MJ. Conflicted Confidence: Academic Oncologists’ Views on Multiplex Pharmacogenomic Testing. J Clin Oncol. 2014; doi:10.1200/JCO.2013.54.8016.